Orchestra BioMed Holdings, Inc. (OBIO) vs Avita Medical Inc. (RCEL)

A side-by-side comparison of Orchestra BioMed Holdings, Inc. and Avita Medical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — OBIO vs RCEL

growth of $100 · dividends reinvested · last 6y
OBIO -47.1% (-10.1%/yr)RCEL -41.1% (-8.4%/yr)RCEL compounded faster over this window
50100150200Start $100202120222023202420252026$53$59
OBIO RCEL

OBIO vs RCEL: by the numbers

  • •OBIO is the larger company ($350M vs $323M market cap).
  • •Both run net losses; RCEL's is the smaller (-56.96% vs -184.60% net margin).
  • •OBIO grew revenue faster over the past five years (148.45% vs 20.94% CAGR).

Metrics side by side

Valuation

MetricOBIORCEL
P/S ratio10.944.27
P/B ratio18.10N/A

Profitability

MetricOBIORCEL
Gross margin99.32%81.56%
Operating margin-154.73%-59.40%
Net margin-184.60%-56.96%
ROE-200.64%N/A
ROIC-56.73%-136.92%

Growth (annualized)

MetricOBIORCEL
Revenue CAGR (5Y)148.45%20.94%
Total return CAGR (5Y)-9.35%-5.28%

Frequently asked

Which has grown faster, OBIO or RCEL?
Over the past five years, OBIO grew revenue faster — OBIO at a 148.45% CAGR versus RCEL at 20.94%.
How have OBIO and RCEL total returns compared?
Over the past 5 years, OBIO delivered -9.35% and RCEL delivered -5.28% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.